GRCL — Gracell Biotechnologies Cashflow Statement
0.000.00%
Last trade - 00:00- $972.69m
- $750.11m
- 49
- 23
- 90
- 54
Annual cashflow statement for Gracell Biotechnologies, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -60.8 | -139 | -212 | -452 | -608 |
| Depreciation | |||||
| Non-Cash Items | 0 | -2.56 | 2.91 | 77.1 | 51 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.05 | 0.703 | -10.8 | 25.3 | 15.1 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -61.9 | -135 | -198 | -305 | -483 |
| Capital Expenditures | -11.4 | -56.4 | -79.4 | -56.7 | -48.4 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -102 | 97.8 | -14.5 | 15.1 | 0.056 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -113 | 41.4 | -93.9 | -41.6 | -48.3 |
| Financing Cash Flow Items | — | — | -3.14 | -14.5 | -3.14 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 139 | 395 | 756 | 1,456 | 33.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -36.5 | 300 | 442 | 1,075 | -374 |